LIPOPROTEIN(A) LEVELS IN SYSTEMIC LUPUS-ERYTHEMATOSUS

被引:0
作者
BORBA, EF
SANTOS, RD
BONFA, E
VINAGRE, CG
PILEGGI, FJC
COSSERMELLI, W
MARANHAO, RC
机构
[1] UNIV HOSP SAO PAULO,SCH MED,DIV RHEUMATOL,SAO PAULO,SP,BRAZIL
[2] UNIV HOSP SAO PAULO,SCH MED,HEART INST SAO PAULO,SAO PAULO,SP,BRAZIL
关键词
LIPOPROTEIN(A); SYSTEMIC LUPUS ERYTHEMATOSUS; ATHEROSCLEROSIS; THROMBOSIS; STEROID THERAPY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine lipoprotein(a) [Lp(a)l levels in systemic lupus erythematosus (SLE) and its possible correlation with thrombosis, disease activity, anticardiolipin antibodies (aCL) and steroid therapy. Methods. Serum Lp(a) levels were determined by radioimmunoassay (RIA) in 34 Caucasian patients with SLE and compared to 66 healthy subjects. Results. In patients with SLE Lp(a) levels were higher than in controls (42 +/- 35 vs 26 +/- 25 mg/dl, p = 0.01). Lp(a) levels were high (greater than or equal to 30 mg/dl) in 56% of the patients with SLE and in 30% of controls (p = 0.02) but were not correlated with the clinical and laboratory findings. Conclusions. Lp(a) levels are significantly higher in patients with SLE and are not influenced by disease activity, thrombosis, aCL and steroid therapy.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 42 条
[1]   THE ASSOCIATION BETWEEN SERUM LP(A) CONCENTRATIONS AND ANGIOGRAPHICALLY ASSESSED CORONARY ATHEROSCLEROSIS - DEPENDENCE ON SERUM LDL LEVELS [J].
ARMSTRONG, VW ;
CREMER, P ;
EBERLE, E ;
MANKE, A ;
SCHULZE, F ;
WIELAND, H ;
KREUZER, H ;
SEIDEL, D .
ATHEROSCLEROSIS, 1986, 62 (03) :249-257
[2]  
ASHERSON RA, 1989, Q J MED, V73, P1103
[3]   CARDIOVASCULAR MANIFESTATIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - PROSPECTIVE-STUDY OF 100 PATIENTS [J].
BADUI, E ;
GARCIARUBI, D ;
ROBLES, E ;
JIMENEZ, J ;
JUAN, L ;
DELEZE, M ;
DIAZ, A ;
MINTZ, G .
ANGIOLOGY, 1985, 36 (07) :431-441
[4]   CORONARY ARTERITIS, OCCLUSION, AND MYOCARDIAL-INFARCTION DUE TO LUPUS-ERYTHEMATOSUS [J].
BONFIGLIO, TA ;
BOTTI, RE ;
HAGSTROM, JW .
AMERICAN HEART JOURNAL, 1972, 83 (02) :153-+
[5]   HEART IN SYSTEMIC LUPUS-ERYTHEMATOSUS AND CHANGES INDUCED IN IT BY CORTICOSTEROID-THERAPY - STUDY OF 36 NECROPSY PATIENTS [J].
BULKLEY, BH ;
ROBERTS, WC .
AMERICAN JOURNAL OF MEDICINE, 1975, 58 (02) :243-264
[6]   DYSLIPOPROTEINEMIA IN SYSTEMIC LUPUS-ERYTHEMATOSUS - EFFECT OF CORTICOSTEROIDS [J].
ETTINGER, WH ;
GOLDBERG, AP ;
APPLEBAUMBOWDEN, D ;
HAZZARD, WR .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (03) :503-508
[7]   ELEVATED APOLIPOPROTEIN-B LEVELS IN CORTICOSTEROID-TREATED PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ETTINGER, WH ;
HAZZARD, WR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (03) :425-428
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   ANTICARDIOLIPIN ANTIBODIES - ISOTYPE DISTRIBUTION AND PHOSPHOLIPID SPECIFICITY [J].
GHARAVI, AE ;
HARRIS, EN ;
ASHERSON, RA ;
HUGHES, GRV .
ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (01) :1-6
[10]   A MULTI-CENTER STUDY OF OUTCOME IN SYSTEMIC LUPUS-ERYTHEMATOSUS .1. ENTRY VARIABLES AS PREDICTORS OF PROGNOSIS [J].
GINZLER, EM ;
DIAMOND, HS ;
WEINER, M ;
SCHLESINGER, M ;
FRIES, JF ;
WASNER, C ;
MEDSGER, TA ;
ZIEGLER, G ;
KLIPPEL, JH ;
HADLER, NM ;
ALBERT, DA ;
HESS, EV ;
SPENCERGREEN, G ;
GRAYZEL, A ;
WORTH, D ;
HAHN, BH ;
BARNETT, EV .
ARTHRITIS AND RHEUMATISM, 1982, 25 (06) :601-611